About

The 21st century will be marked by the convergence of artificial intelligence, fuelled by Moore's Law ('Mursla' pronounced in Japanese), and the increasing ability to decode the complex language of biology ('Bio')

Leadership

  • Serial biotech entrepreneur in the Extracellular Vesicle (EV) field
  • A decade of experience in healthcare investment banking at J.P. Morgan
  • Multiple patents and publications in EV biomedical applications
  • Closed over 20 transactions valued $70B
  • Postgraduate research in biophysics and nanoelectronics at the University of Cambridge (Cavendish Laboratory)
  • Received his Master of Science in Management from HEC Paris (Grande Ecole) 
Pierre Arsène

Founder & CEO

  • Over a decade of scientific experience in the liquid biopsy space, including EV-based diagnostics
  • Many scientific publications in the fields of cfDNA, EVs, biochips, microfluids and automation
  • Developed several patented technologies for EV diagnostics and isolation
  • Received his Ph.D in Bioengineering Systems from the MIT Portugal Programme
  • Received his MSc in Bioengineering and Nanosystems from the Instituto Superior Technico
Tomás Dias, PhD

Chief Technology Officer

  • Over 25 years in various life science leadership positions in both the US and the UK
  • Brought >20 innovative products to market from R&D to launch, including in vitro diagnostics (IVD) tests
  • Led 40-centre UK-based clinical trial and 20-centre US observational study
  • Received her Ph.D. in Molecular Biology from the University of Southern Carolina
  • Post doctoral research in genetics at the University of Cambridge
Karin Schmitt, PhD

Chief Operating Officer

Partners